{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:08:28Z","timestamp":1791864508683,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.juro.2012.11.089","type":"journal-article","created":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T04:17:09Z","timestamp":1353385029000},"page":"1804-1810","source":"Crossref","is-referenced-by-count":82,"title":["Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity"],"prefix":"10.1097","volume":"189","author":[{"given":"Chun-Hou","family":"Liao","sequence":"first","affiliation":[{"name":"Departments of Urology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, Buddhist Tzu Chi General Hospital (HCK) and Tzu Chi University (HCK), Hualien, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Departments of Urology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, Buddhist Tzu Chi General Hospital (HCK) and Tzu Chi University (HCK), Hualien, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2012.11.089_bib1","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study","volume":"50","author":"Leibson","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.juro.2012.11.089_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinics treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11592790-000000000-00000","article-title":"Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder","volume":"34","author":"Oefelein","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.juro.2012.11.089_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","article-title":"Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder","volume":"64","author":"Wagg","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.juro.2012.11.089_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/nau.20923","article-title":"The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2012.11.089_bib7","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.juro.2012.11.089_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cger.2010.08.008","article-title":"Frailty defined by deficit accumulation and geriatric medicine defined by frailty","volume":"27","author":"Rockwood","year":"2011","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.juro.2012.11.089_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/nau.20842","article-title":"Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Fourth International Consultation on Incontinence","volume":"29","author":"DuBeau","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2012.11.089_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2008.11.110","article-title":"What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection","volume":"181","author":"Khan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib12","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of botulinum toxin type A for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib16","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.juro.2008.08.030","article-title":"Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population","volume":"180","author":"White","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2012.11.089_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1464-410x.1999.00121.x","article-title":"Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function","volume":"84","author":"Abrams","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2012.11.089_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.juro.2012.11.089_bib21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bjp.0706147","article-title":"Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing","volume":"144","author":"Mansfield","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2012.11.089_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11357-010-9163-7","article-title":"Aging differentially modifies agonist-evoked mouse detrusor contraction and calcium signals","volume":"33","author":"Gomez-Pinilla","year":"2011","journal-title":"Age (Dordr)"},{"key":"10.1016\/j.juro.2012.11.089_bib23","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.089_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","article-title":"Adverse events after botulinum A toxin injection for neurogenic voiding disorders","volume":"43","author":"De Laet","year":"2005","journal-title":"Spinal Cord"},{"key":"10.1016\/j.juro.2012.11.089_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cot\u00e9","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712055930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712055930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2012.11.089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:54:22Z","timestamp":1651186462000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2012.11.089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1016\/j.juro.2012.11.089"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2012.11.089","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718001856.793475211","asserted-by":"object"}]},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}